Guizhou Sanli Pharmaceutical Co Ltd (603439) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.021x

Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.19 Million ≈ $4.86 Million USD) by net assets (CN¥1.55 Billion ≈ $226.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Guizhou Sanli Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 603439 total liabilities for a breakdown of total debt and financial obligations.

Guizhou Sanli Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Acast AB ST:ACAST	0.057x
BridgeBio Oncology Therapeutics, Inc. NASDAQ:BBOT	-0.103x
Afya Ltd NASDAQ:AFYA	0.106x
Compania de Transporte de Energia Electrica en Alta Tension Transener SA BA:TRAN	0.118x
Zhejiang Jasan Holding Group Co Ltd SHG:603558	0.057x
Regal Partners Ltd AU:RPL	0.048x
ECOVE Environment Corp TWO:6803	-0.287x
Braskem SA Class A NYSE:BAK	0.055x

Annual Cash Flow Conversion Efficiency for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Guizhou Sanli Pharmaceutical Co Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.59 Billion ≈ $233.34 Million	CN¥107.07 Million ≈ $15.67 Million	0.067x	-58.52%
2023-12-31	CN¥1.71 Billion ≈ $250.13 Million	CN¥276.70 Million ≈ $40.49 Million	0.162x	-31.66%
2022-12-31	CN¥1.24 Billion ≈ $181.19 Million	CN¥293.29 Million ≈ $42.92 Million	0.237x	+57.68%
2021-12-31	CN¥1.03 Billion ≈ $151.02 Million	CN¥155.04 Million ≈ $22.69 Million	0.150x	+133.21%
2020-12-31	CN¥981.88 Million ≈ $143.68 Million	CN¥63.25 Million ≈ $9.26 Million	0.064x	-63.92%
2019-12-31	CN¥651.09 Million ≈ $95.27 Million	CN¥116.24 Million ≈ $17.01 Million	0.179x	+22.74%
2018-12-31	CN¥518.02 Million ≈ $75.80 Million	CN¥75.35 Million ≈ $11.03 Million	0.145x	+19.81%
2017-12-31	CN¥473.36 Million ≈ $69.27 Million	CN¥57.47 Million ≈ $8.41 Million	0.121x	+48.93%
2016-12-31	CN¥430.59 Million ≈ $63.01 Million	CN¥35.10 Million ≈ $5.14 Million	0.082x	-46.96%
2015-12-31	CN¥216.53 Million ≈ $31.68 Million	CN¥33.28 Million ≈ $4.87 Million	0.154x	+2870.82%
2014-12-31	CN¥108.92 Million ≈ $15.94 Million	CN¥563.46K ≈ $82.45K	0.005x	-98.81%
2013-12-31	CN¥69.09 Million ≈ $10.11 Million	CN¥30.09 Million ≈ $4.40 Million	0.435x	--

About Guizhou Sanli Pharmaceutical Co Ltd

SHG:603439 China Drug Manufacturers - Specialty & Generic

Market Cap

$666.61 Million

CN¥4.56 Billion CNY

Market Cap Rank

#11140 Global

#3316 in China

Share Price

CN¥11.14

Change (1 day)

-0.98%

52-Week Range

CN¥10.49 - CN¥14.17

All Time High

CN¥41.67